Back to results
US 8,911,722 B2Granted
Modulation of yeast-based immunotherapy products and responses
AssigneeThe Regents of the University of Colorado, a body corporate
InventorsDonald Bellgrau, Beth Tamburini
Life of this patent
Estimating the term…
Abstract
Disclosed are methods to modulate yeast-based immunotherapy products and the immune responses, prophylactic responses, and/or therapeutic responses elicited by such products. Also disclosed are modified yeast-based immunotherapy products, kits and compositions.
Claims12
A method to inhibit the production or survival of CD4+ TH17 cells in a subject, comprising administering to a subject:
- a) a yeast-based immunotherapy composition comprising a whole yeast and an antigen;
- and
- b) an agent that inhibits the production or survival of CD4+ TH17 cells,
- wherein the agent inhibits interleukin-6 (IL 6), and wherein the agent is selected from an antibody or antigen binding portion thereof, or a soluble inactive form of IL-6 or its receptor;
- wherein the administration of the agent is prior to, in conjunction with, and/or following administration of the yeast-based immunotherapy composition, and wherein the production or survival of CD4+ TH17 cells is inhibited in the subject.
2 more elements
A composition comprising:
- a) a yeast-based immunotherapy composition comprising a whole yeast and an antigen;
- and
- b) an agent that inhibits the production or survival of CD4+ TH17 cells, wherein the agent
- inhibits interleukin-6 (IL 6), and wherein the agent is selected from an antibody or antigen binding portion thereof, or a soluble inactive form of IL-6 or its receptor.
1 more element
Dependencies are inferred from the claim text.